Hospital
Columbia ST Mary's Hospital Ozaukee, INC.
Columbia ST Mary's Hospital Ozaukee, INC. was paid $2.10M by Medicaid between Jan 2018 and Mar 2022, across 151 billing codes. Its largest line is 96361, Intravenous infusion, hydration; each additional hour — 12% of everything it billed.
33Billing provider infoCOLUMBIA ST MARY'S HOSPITAL OZAUKEE, INC.
MEQUON, WI 53097
MEQUON, WI 53097
33aNPI1316000706assigned 12/18/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.10M
24GClaims146,032
24DCodes billed151
24AFirst – last monthJan 2018 – Mar 2022
Compared with peers
Next to other General Acute Care Hospital providers in Wisconsin
Rank by total paid#35 of 60
Median peer was paid$2.90M
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 28,651 | $415K | |
| 2019 | 32,560 | $406K | |
| 2020 | 31,016 | $475K | |
| 2021 | 45,178 | $642K | |
| 2022 | 8,627 | $162K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 96361 | Intravenous infusion, hydration; each additional hour | 12% | 2,761 | 2,156 | $257K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.9% | 4,587 | 3,971 | $166K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.8% | 3,064 | 2,713 | $144K |
| 80053 | Comprehensive metabolic panel | 6.8% | 6,893 | 5,546 | $143K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.8% | 3,832 | 3,145 | $121K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.5% | 1,488 | 1,255 | $93K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.9% | 1,906 | 1,394 | $82K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 3.9% | 1,509 | 1,144 | $81K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.0% | 9,447 | 7,250 | $62K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.8% | 3,137 | 2,277 | $60K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.8% | 1,148 | 1,010 | $58K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.7% | 1,568 | 1,333 | $57K |
139 more codes
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.6% | 1,524 | $54K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.2% | 938 | $46K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 2.0% | 1,134 | $41K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.9% | 4,722 | $40K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 1.7% | 2,962 | $35K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.6% | 208 | $33K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.5% | 497 | $32K |
| 81003 | 1.4% | 1,802 | $29K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 663 | $27K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.3% | 2,667 | $27K |
| 99213 | Doctor's office visit, returning patient (routine) | 1.2% | 1,025 | $26K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.2% | 779 | $25K |
| 82962 | <1% | 2,345 | $18K | |
| 84484 | <1% | 2,335 | $17K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,258 | $17K |
| 81025 | <1% | 1,836 | $16K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,948 | $16K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,477 | $16K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 298 | $15K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 518 | $15K |
| 83880 | <1% | 710 | $13K | |
| 87077 | <1% | 810 | $10K | |
| 85610 | <1% | 1,928 | $10K | |
| 86850 | <1% | 406 | $9K | |
| 83690 | <1% | 1,905 | $9K | |
| G0378 | Hospital observation service, per hour | <1% | 1,018 | $9K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,333 | $9K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 993 | $8K |
| 81001 | <1% | 2,865 | $8K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 883 | $7K |
| 83735 | <1% | 1,645 | $6K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 263 | $6K |
| 83605 | <1% | 1,031 | $6K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 67 | $5K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 181 | $5K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 178 | $5K |
| 80061 | Lipid panel | <1% | 478 | $5K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 181 | $5K |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | <1% | 190 | $5K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 108 | $5K |
| 85027 | <1% | 856 | $5K | |
| 90837 | Psychotherapy session, about an hour | <1% | 498 | $4K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 66 | $3K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 549 | $3K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,066 | $3K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 497 | $3K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,596 | $3K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 149 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,384 | $3K |
| 80143 | <1% | 125 | $3K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 15 | $3K |
| 76830 | Ultrasound, transvaginal | <1% | 65 | $2K |
| 74018 | <1% | 146 | $2K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 91 | $2K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,602 | $2K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 120 | $2K |
| 87634 | <1% | 43 | $2K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 16 | $2K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 32 | $2K |
| 86901 | <1% | 523 | $2K | |
| 87186 | <1% | 364 | $2K | |
| 76642 | <1% | 41 | $1K | |
| 86900 | <1% | 523 | $1K | |
| 93971 | <1% | 43 | $1K | |
| 84702 | <1% | 86 | $1K | |
| 82728 | <1% | 71 | $1K | |
| 73630 | <1% | 247 | $1K | |
| 85379 | <1% | 160 | $1K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 141 | $1K |
| 86780 | <1% | 106 | $977.57 | |
| 80179 | <1% | 125 | $972.39 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 45 | $969.14 |
| 87070 | <1% | 88 | $961.52 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 206 | $927.10 |
| 71250 | <1% | 28 | $911.29 | |
| 86803 | <1% | 85 | $887.93 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,625 | $834.95 |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 26 | $786.46 |
| 84439 | <1% | 83 | $763.01 | |
| 87340 | <1% | 63 | $582.74 | |
| 83540 | <1% | 57 | $573.52 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,116 | $564.76 |
| 86140 | <1% | 160 | $451.30 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,736 | $444.01 |
| 76770 | <1% | 14 | $425.13 | |
| 82565 | <1% | 17 | $413.89 | |
| 86762 | <1% | 29 | $406.73 | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 13 | $402.54 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,359 | $385.67 |
| 83550 | <1% | 53 | $365.52 | |
| 94060 | <1% | 41 | $339.07 | |
| 87040 | <1% | 47 | $328.03 | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,877 | $308.09 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,205 | $223.41 |
| Q3014 | Telehealth originating site facility fee | <1% | 15 | $162.12 |
| 82607 | <1% | 26 | $159.08 | |
| 94729 | <1% | 37 | $149.29 | |
| 87205 | <1% | 65 | $144.80 | |
| 87081 | <1% | 30 | $132.00 | |
| 80329 | <1% | 134 | $115.92 | |
| 85730 | <1% | 35 | $109.10 | |
| 85018 | <1% | 63 | $86.89 | |
| 97162 | <1% | 16 | $84.38 | |
| 83516 | <1% | 22 | $76.34 | |
| 99152 | <1% | 196 | $70.57 | |
| 86592 | <1% | 13 | $66.70 | |
| 85652 | <1% | 33 | $62.13 | |
| 90686 | <1% | 116 | $60.25 | |
| 94726 | <1% | 12 | $52.02 | |
| 80047 | <1% | 13 | $49.39 | |
| 85007 | <1% | 37 | $48.12 | |
| 88342 | <1% | 45 | $36.19 | |
| 82043 | <1% | 15 | $35.27 | |
| 80320 | <1% | 554 | $31.69 | |
| 90674 | <1% | 58 | $25.40 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,649 | $18.53 |
| 96376 | <1% | 623 | $17.71 | |
| 73564 | <1% | 12 | $16.88 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,029 | $12.04 |
| A9270 | Non-covered item or service | <1% | 8,927 | $9.66 |
| 99153 | Mod sedat endo service >5yrs | <1% | 370 | $6.77 |
| 36416 | <1% | 1,307 | $5.28 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 364 | $2.78 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 975 | $2.19 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,352 | $1.47 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 901 | $1.43 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 276 | $1.18 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 161 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 51 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 39 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 52 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 31 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 100 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 177 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 146 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 37 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 98 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 30 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 22 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHANSELMAN, MATTHEW (CFO)
| Provider | Location | Paid |
|---|---|---|
| Columbia ST Mary's Hospital Ozaukee, INC. | Mequon, WI | $807K |
| Columbia ST Mary's Hospital Ozaukee, INC. | Mequon, WI | $9K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.